
Xspray Pharma - Investment Case Materializing

Redeye envisions an exciting period on the horizon for Xspray Pharma following the resolution of the Dasynoc patent litigation with BMS. We consider the settlement a validation of Xspray's technology and perceive a risk reduction associated with the investment case. As a result, we rework our forecasts and DCF, adjusting our fair value range accordingly.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Xspray Pharma - Investment Case Materializing